Green chemistry
Here, Dave Elder reflects on the pharma industry’s efforts to get greener; highlighting the confounding issues that mean it is not always easy to achieve.
List view / Grid view
Articles
Prioritising bold innovation throughout the pandemic and beyond
Following his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
Challenges in downstream purification of advanced therapies
John Liddell, Chief Technologist at the Centre for Process Innovation (CPI), writes about the challenges associated with gene therapy products, which constitute a major portion of the overall cell and gene therapy market.
Portable NIR sensors in medicinal plant quality control
In the quest for fast and reliable ingredient analysis, Christian W Huck, Krzysztof B Bec and Justyna Grabska from the Institute of Analytical Chemistry and Radiochemistry at the University of Innsbruck, consider the use of portable NIR spectroscopy, comparing the results from standard and miniaturised sensors.
Pharmaceutical analysis with portable spectrometers
Richard Crocombe of Crocombe Spectroscopic Consulting surveys the use of portable spectrometers in pharmaceutical manufacturing, with an emphasis on vibrational spectroscopy. Ideal and typical features of portable spectrometers are reviewed, alongside explanation of why device characteristics and sample presentation are critical to obtaining meaningful results.
Coupling large molecules with targeting and delivery mechanisms to augment intracellular delivery
Most intracellular drug targets remain intractable due to cellular membranes effectively denying large foreign molecules entry into the cytoplasm. Over recent decades, several technologies that enable biologics to enter cells have emerged, but successes remain limited to date. Here, Sapreme Technologies’ Miriam Bujny, Chief Development Officer, and Guy Hermans, Chief…
Radiomolecular precision oncology: a comprehensive treatment approach with high potential
A significant obstacle still faced in oncology is damage to healthy cells inflicted during treatment, which robs patients of their quality of life while battling cancer. Targeted radionuclide therapy (TRT) is a type of radiomolecular precision oncology that addresses this issue by deploying cancer-killing radiation directly to tumour cells, with…
2022: Advancing across the blood-brain barrier
The brain is protected by the blood-brain barrier, a multi-layered structure which helps to protect it from the invasion of pathogens or unwanted substances and limits drug transport into the brain via the bloodstream. Here, Dr Oliver Ernst and Dr Heiko Manninga from German biotech company NEUWAY Pharma share details of…
Novel excipients for solubility enhancement
Lubrizol Life Science Health colleagues Nick DiFranco, Global Market Segment Manager for Oral Treatments, and Joey Glassco, Senior Global Market Manager for Parenteral Drug Delivery, explore the use of amorphous solid dispersions and polymeric micelles for solubility enhancement.
Drug Delivery In-Depth Focus 2022
Articles featured in this in-depth focus discuss a technology enabling drugs to be delivered across the blood-brain barrier, the potential of targeted radionuclide therapy as a precision oncology treatment and novel bioconjugation methods to improve biologics drug delivery.
QA/QC NIR & Raman In-Depth Focus 2022
Articles in this in-depth focus explore the applications of portable spectrometers and review their critical features, as well as comparing the results of standard and miniaturised NIR spectroscopy sensors in medicinal plant QC.
European Pharmaceutical Review Issue 1 2022
In our latest journal, discover the innovations enabling drugs to be delivered across the blood-brain barrier, the challenges associated with downstream purification of cell and gene therapies, as well as applications of NIR spectroscopy in ingredient analysis. Also featured in this issue, explore the development and future potential of radiomolecular…
2021 bio/pharma financial round-up
European Pharmaceutical Review investigates the financial results of some of the top 10 pharma and biopharma companies worldwide.
Phase I oncology studies: rule- versus model-based design
In this article, Karen Ooms, Head of Statistics at Quanticate, compares the rule- and model-based approaches to Phase I trial design, exploring their benefits and weaknesses in defining maximum tolerated dose for oncology products.
The microbiome: unlocking the Fourth Industrial (Bio) Revolution
The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
